DCM
TOVX icon

DAFNA Capital Management’s Theriva Biologics TOVX Stock Holding History

DAFNA Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-21
Closed -$283K – 51
2013
Q4 		$283K Buy
+21
New +$265K 0.29% 43

Other funds holding TOVX

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DAFNA Capital Management's TOVX Position: Q1 2014 in Review

DAFNA Capital Management sold out of Theriva Biologics (TOVX) in Q1 2014, closing a stake of 21 shares — an estimated $283K sold.

DAFNA Capital Management first reported a position in TOVX in Q4 2013 and held it in 1 quarter. The position peaked at $283K in Q4 2013. 27 funds tracked by Wall St. Rank hold TOVX as of Q1 2014.

  • DAFNA Capital Management reported no remaining Theriva Biologics position as of Q1 2014 after selling out during the quarter.
  • DAFNA Capital Management sold 21 Theriva Biologics shares in Q1 2014, an estimated $283K.
  • DAFNA Capital Management first reported a position in Theriva Biologics in Q4 2013 and held it in 1 quarter.
  • DAFNA Capital Management's Theriva Biologics position peaked at $283K in Q4 2013.
  • 27 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2014.

Based on DAFNA Capital Management's 13F filing for Q1 2014, filed 15 May 2014.